Abstract:Objectives: Differentiating true progression or recurrence (TP/TR) from therapy-related changes (TRC) is complex in brain tumours. Amide proton transfer-weighted (APT) imaging is a chemical exchange saturation transfer (CEST) MRI technique that may improve diagnostic accuracy during radiological follow-up. This systematic review and meta-analysis elucidated the level of evidence and details of state-of-the-art imaging for APT-CEST in glioma and brain metastasis surveillance. Methods: PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched for original articles about glioma and metastasis patients who received APT-CEST imaging for suspected TP/TR within 2 years after (chemo)radiotherapy completion. Modified Quality Assessment of Diagnostic Accuracy Studies-2 criteria were applied. A meta-analysis was performed to pool results and to compare subgroups. Results: Fifteen studies were included for a narrative synthesis, twelve of which (500 patients) were deemed sufficiently homogeneous for a meta-analysis. Magnetisation transfer ratio asymmetry performed well in gliomas (sensitivity 0.88 [0.82-0.92], specificity 0.84 [0.72-0.91]) but not in metastases (sensitivity 0.64 [0.38-0.84], specificity 0.56 [0.33-0.77]). APT-CEST combined with conventional/advanced MRI rendered 0.92 [0.86-0.96] and 0.88 [0.72-0.95] in gliomas. Tumour type, TR prevalence, sex, and acquisition protocol were sources of significant inter-study heterogeneity in sensitivity (I2 = 62.25%; p < 0.01) and specificity (I2 = 66.31%; p < 0.001). Conclusion: A growing body of literature suggests that APT-CEST is a promising technique for improving the discrimination of TP/TR from TRC in gliomas, with limited data on metastases. Clinical relevance statement: This meta-analysis identified a utility for APT-CEST imaging regarding the non-invasive discrimination of brain tumour progression from therapy-related changes, providing a critical evaluation of sequence parameters and cut-off values, which can be used to improve response assessment and patient outcome. Key points: Therapy-related changes mimicking progression complicate brain tumour treatment. Amide proton imaging improves the non-invasive discrimination of glioma progression from therapy-related changes. Magnetisation transfer ratio asymmetry measurement seems not to have added value in brain metastases.

Quantitative Amide Proton Transfer Imaging with Reduced Interferences from Magnetization Transfer Asymmetry for Human Brain Tumors at 3T

Three-dimensional Simultaneous Brain Mapping of T1, T2, T2*and Magnetic Susceptibility with MR Multitasking

Quantitative assessment of amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging with extrapolated semi-solid magnetization transfer reference (EMR) signals: Application to a rat glioma model at 4.7 tesla.

Three-dimensional simultaneous brain T 1 , T 2 , and ADC mapping with MR Multitasking.

Amid proton transfer (APT) and magnetization transfer (MT) MRI contrasts provide complimentary assessment of brain tumors similarly to proton magnetic resonance spectroscopy imaging (MRSI)

Quantitative Assessment of Amide Proton Transfer (apt) and Nuclear Overhauser Enhancement (noe) Imaging with Extrapolated Semisolid Magnetization Transfer Reference (emr) Signals: Ii. Comparison of Three Emr Models and Application to Human Brain Glioma at 3 Tesla

Quantitative Assessment of the Effects of Water Proton Concentration and Water T-1 Changes on Amide Proton Transfer (apt) and Nuclear Overhauser Enhancement (noe) Mri: the Origin of the Apt Imaging Signal in Brain Tumor

B0 Correction for 3T Amide Proton Transfer (APT) MRI Using a Simplified Two-Pool Lorentzian Model of Symmetric Water and Asymmetric Solutes

Amide-proton-transfer MRI signal as biomarker of glioma as assessed by image-guided needle biopsy

Improving the Detection Sensitivity of Ph‐weighted Amide Proton Transfer MRI in Acute Stroke Patients Using Extrapolated Semisolid Magnetization Transfer Reference Signals

Direct Radiofrequency Saturation Corrected Amide Proton Transfer Tumor MRI at 3T

Three-dimensional simultaneous brain T<sub>1</sub>, T<sub>2</sub>, and ADC mapping with MR Multitasking

Differentiation of Malignant and Benign Head and Neck Tumors with Amide Proton Transfer-Weighted MR Imaging

Apt-Weighted And Noe-Weighted Image Contrasts In Glioma With Different Rf Saturation Powers Based On Magnetization Transfer Ratio Asymmetry Analyses

Fast, Reliable 3D Amide Proton Transfer Imaging of Brain Tumors at 3T with Variably-accelerated Sensitivity Encoding (vSENSE).

[Progress in Clinical Research of Amide Proton Transfer Imaging].

Influences of Experimental Parameters on Chemical Exchange Saturation Transfer (CEST) Metrics of Brain Tumors Using Animal Models at 4.7T

Combining Amide Proton Transfer-Weighted and Arterial Spin Labeling Imaging to Differentiate Solitary Brain Metastases from Glioblastomas

Differentiation of Low- and High-Grade Pediatric Gliomas with Amide Proton Transfer Imaging: Added Value Beyond Quantitative Relaxation Times

Preliminary Demonstration of in Vivo Quasi-Steady-state CEST Postprocessing-Correction of Saturation Time and Relaxation Delay for Robust Quantification of Tumor MT and APT Effects.

Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases